A. Montesa

632 total citations
16 papers, 54 citations indexed

About

A. Montesa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, A. Montesa has authored 16 papers receiving a total of 54 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in A. Montesa's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Renal cell carcinoma treatment (4 papers). A. Montesa is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Renal cell carcinoma treatment (4 papers). A. Montesa collaborates with scholars based in Spain, Finland and Russia. A. Montesa's co-authors include Urbano Anido, J. Lambea, María José Méndez-Vidal, E. Fernández-Parra, Carolina Hernández, Enrique Gallardo, Álvaro Pinto, Isabel Chirivella, Marta Guix and Juan Manuel Sepúlveda-Sánchez and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Clinical Medicine.

In The Last Decade

A. Montesa

12 papers receiving 54 citations

Peers

A. Montesa
Ariel Galapo Kann Brazil
Adam Donoghue Canada
Jennifer Margrave United States
Elena Almagro Spain
Tienan Yi China
Sara Arce‐Gallego Spain
Á. Montesa Pino Spain
Lynn Tanoue United States
Laura Monovich United States
The Cancer Genome Atlas Research Network United States
Ariel Galapo Kann Brazil
A. Montesa
Citations per year, relative to A. Montesa A. Montesa (= 1×) peers Ariel Galapo Kann

Countries citing papers authored by A. Montesa

Since Specialization
Citations

This map shows the geographic impact of A. Montesa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Montesa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Montesa more than expected).

Fields of papers citing papers by A. Montesa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Montesa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Montesa. The network helps show where A. Montesa may publish in the future.

Co-authorship network of co-authors of A. Montesa

This figure shows the co-authorship network connecting the top 25 collaborators of A. Montesa. A scholar is included among the top collaborators of A. Montesa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Montesa. A. Montesa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Jurado, J.M., Vanesa Gutiérrez, Miguel‐Ángel Berciano‐Guerrero, et al.. (2025). Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 14(7). 2499–2499.
2.
Smith, Matthew R., Maha Hussain, Fred Saad, et al.. (2022). Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. Journal of Clinical Oncology. 40(6_suppl). 13–13. 7 indexed citations
3.
Puente, Javier, Urbano Anido, Miguel Ángel Climent, et al.. (2020). Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. Therapeutic Advances in Medical Oncology. 12. 3863535107–3863535107. 2 indexed citations
4.
5.
6.
Lozano, Rebeca, Elena Castro, Josep M. Piulats, et al.. (2019). Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.. Journal of Clinical Oncology. 37(7_suppl). 264–264. 4 indexed citations
7.
Romero-Laorden, Nuria, Núria Laínez, Susana Hernando, et al.. (2019). Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study. Annals of Oncology. 30. v344–v344. 2 indexed citations
8.
Méndez-Vidal, María José, Urbano Anido, Isabel Chirivella, et al.. (2018). Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacology and Toxicology. 19(1). 77–77. 20 indexed citations
9.
10.
Romero-Laorden, Nuria, et al.. (2017). Limited value of currently used germline brca mutations predictive tools in prostate cancer. Annals of Oncology. 28. v286–v286.
11.
Berciano‐Guerrero, Miguel‐Ángel, Rocío Lavado-Valenzuela, A. Montesa, et al.. (2017). Different patterns of non immediate allergic reaction to BRAF inhibitor in two patients with metastatic melanoma.. Journal of Clinical Oncology. 35(15_suppl). e21052–e21052.
12.
Lambea, J., et al.. (2016). The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports. 18(11). 66–66. 6 indexed citations
13.
Pérez, José M., Luis Gustavo Perez‐Rivas, A. Montesa, et al.. (2012). Hypoxia-inducible factor (HIF) 1α and 2α as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC).. Journal of Clinical Oncology. 30(15_suppl). 4630–4630. 5 indexed citations
14.
Cobo, Manuel, et al.. (2009). Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). e19013–e19013. 1 indexed citations
15.
16.
Cobo, Manuel, et al.. (2006). Primary signet-ring cell adenocarcinoma of the urinary bladder: a case report. 29(4). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ariel Galapo Kann Breakdown of academic impact, for papers by Adam Donoghue Breakdown of academic impact, for papers by Jennifer Margrave Breakdown of academic impact, for papers by Elena Almagro Breakdown of academic impact, for papers by Tienan Yi Breakdown of academic impact, for papers by Sara Arce‐Gallego Breakdown of academic impact, for papers by Á. Montesa Pino Breakdown of academic impact, for papers by Lynn Tanoue Breakdown of academic impact, for papers by Laura Monovich Breakdown of academic impact, for papers by The Cancer Genome Atlas Research Network
Rankless by CCL
2026